Research Center for Thalassemia & Hemoglobinopathy, Joundishapur University of Medical Science, Ahvaz, Iran

In patients with significant thalassemia, iron excess is a serious issue. Treatment of these individuals involves using an iron chelator strategy that is efficient, secure, and has a high compliance rate. The purpose of this study was to evaluate the effectiveness and safety of the sequential deferoxamine and deferasirox treatment in patients with significant thalassemia in the Iranian province of Khuzestan.

There were 62 cases investigated, ranging in age from 2 to 30. A course of treatment included 4 days of deferasirox and 3 days of deferoxamine. The experiment lasted for six months. By comparing the ferritin levels before and after therapy, the efficacy was evaluated.

Serum ferritin fell dramatically from 3590 ng/ml to 2563 ng/ml. 21% of the participants in the research had at least one side effect.

This novel regimen has a high rate of efficacy, little harmful side effects, and reasonable compliance.

Key words: Sequential, dextromethorphan, and major thalassemia.

Iron over-burden is an unavoidable issue in significant thalassemia patients. Each unit of pressed platelet contains 200 - 250 mg iron (1-2). The body has not dynamic component to discharge iron gathering. Iron over-burden can cause tissue harm, for example, cardiovascular breakdown, liver infection, endocrine aggravations, which could cause inevitable passing (3-4). There have been laid out confirmations that iron chelator drugs decrease tissue harms and further develop future in these patients (7). These patients require a ceaseless iron chelator drugs. The points of iron chelator treatment in these patients are; first and foremost, diminish iron weight, furthermore, lessen hazard of tissue harm particularly in unambiguous key organs like heart and liver, thirdly, further develop life endurance, fourthly, give 24-hour security from the poisonous impacts of iron, for example, Labile Plasma Iron, lastly, decrease hole liberated from iron chelator drugs (8).High adequacy, low unfavorable impacts, high consistence, and minimal expense ought to be added to the points referenced previously. Lately numerous different iron chelators regimens were utilized, which incorporate monotheray, consolidated and elective successive regimens (9-13). This venture concentrated on adequacy of exchanging successive Deferasirox (Osveral)/Deferoxamine chelating treatment to diminished serum ferritin.

This preliminary was performed on 62 significant thalassemia patients, who went to Exploration Community for Thalassemia and Hemoglobinopathy-Shafa emergency clinic connected with Ahwaz Joundishapur of Clinical Science. In these cases 31 were male and 31 female, matured between 6 to 30 years of age (mean age 18.5). The term of treatment was a half year. For everyone Cell Blood Count (CBC), serum ferritin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), BUN, creatinine, urinalysis, visual and hear-able assessment and echocardiography were tried before treatment and every month after treatment. The viability of routine was assessed by examination of serum ferritin level when treatment. All patients were treated in a mean all out everyday portion of OSV (Osveh co) 23 mg/kg( range 17.2-30) 4 days per week (Saturday until Tuesday), single portion 30 minutes before breakfast alongside Deferoxamine (Novartis pharma co) 50 mg/kg (range 30-55) 12 hours subcutaneously for three one days from now( Wednesday until Friday). Informed assent was endorsed by all guardians prior to beginning treatment. In the wake of gathering information, measurable examination was performed by SPSS 16.0.2. Contrasts were viewed as huge at PV <0.05.

Out of the 62 patients 7(6.3%) ended therapy for clinical and individual reasons during first month of treatment. Consistence reaction was great (95%). Mean serum ferritin focus declined from 3590 ng/ml (range 1200-7200) to 2563 ng/ml (range 750-5800),

which diminished essentially (P 0.005). During preliminary 13 of patients (21%) experienced no less than one general antagonistic medication response (Table1). These occasions happened mostly in the primary seven day stretch of treatment and they were gentle response. Liver compounds expanded in AST and ALT 16% and 18% separately, which generally rised two to multiple times of typical level. Luckily, AST and ALT diminished subsequent to beginning treatment in 17% and 27% of patients separately. .Secondary effects, for example, migraine, proteinuria, looseness of the bowels, anorexia and stomach torment were seen in under 3% of patients. The main unfriendly impact of the convention was raised serum creatinine, which happened in 13 patients. All creatinine rising were in the ordinary reach. Deferoxamine implantation was not related with canker at the site of imbuement or unfavorably susceptible responses.

The problem of iron overload in beta thalassemia patients is predicted. Chelating agents for iron lessen tissue damage. An electronic pump is required for gradual infusion over 8–12 hours, 5–7 nights per week, during dextromethorphan monotherapy (14). Thus, the majority of patients reject this therapy (14-16). Similar to DFO, the other iron chelator medication, Deferasirox, does not offer 24-hour chelating coverage due to its short half-life of 3–4 hours. Due to these medications' short half-lives (20–30 minutes for the former and 3–4 hours for the latter) and quick drop in plasma levels, monotherapy has not been able to fully achieve all therapeutic aims (14).Deferasirox is a powerful oral iron chelator with a long half life, which could be utilized as monotherapy. It could furnish consistent hole free chelation inclusion with a solitary everyday portion, and has an effective and particular job on organs like heart and live (8, 17-18). Deferasirox could deliver an adequate 24 hours iron chelator inclusion. Be that as it may, the viability on the high iron over-burden is problematic. It couldn't accomplish a negative iron offset even with most elevated suggested portion, which could cause cut off secondary effects. Thus, iron chelator medications couldn't really give all helpful objectives in these patients in view of the monotherapy approach (19). Blend treatment previously rehearsed in significant thalassemia by Anderson et al. They utilized mix Deferoxamine/Deferiprone and proposed a few possible benefits with this routine [20]. Prescriptions with various properties and systems might get to various iron pools. The particle of Deferasirox is little and can undoubtedly go into cells and can move iron into plasma for Deferoxamine chelation (10-13, 21-26).

This methodology of treatment is an adaptable routine ,which would permit the clinicians lessen the daily Deferoxamine infusions and increment the oral portions with high viability and low poisonousness (20,27-28).The adequacy of the rotating utilization of deferiprone and DFO was at first detailed by Aydinok et al in non-controlled clinical review (29). In present review serum ferritin diminished altogether. This routine was related with insignificant antagonistic impact. The major serious result of this routine was creatinine rising which happened in 21% of patients. All creatinine rising were in ordinary cutoff points. In monotherapy approach this unfavorable medication response is high [30].Sequential Deferoxamine/OSV is another convention to date with benefits of additional time iron chelator inclusion, OK adequacy and consistence and lower aftereffects. The substituting utilization of both chelator is powerful in high iron stacked and clinicians could give patients a deferasirox - free period to forestall significant secondary effects. The main detriment of this routine is the hole of the free iron chelator time.

The findings of this study's conclusion demonstrated that sequential therapy of iron chelator medications results in a significant decrease in serum ferritin with high compliance and no noticeable harm.

1. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239–52.

2. Khalifa AS, Sheir S, el Magd LA, El Tayeb H, El Lamie O, Khalifa A, et al. The kidney in betathalassemia major. Acta Haematol1985; 74:60

3. Ishizaka N, Saito K, Mitani H, Yamazaki L, Sata M, Usui S, et al. Iron overload augments angiotensin IIinduced cardiac fibrosis and promotes neointima formation. Circulation. 2002.106:1840–6.

4. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood 2004;104:34–9.

5. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994.331:567–73.

6. Modell B, Khan M, Darlison M. Survival in beta-thalassemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000. 355:2051–2.

7. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A,,et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994.331:574–8.

8. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;182:277–87.

9. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Séchaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Launcet 2003;361:1597–602

10. Hoffbrand AV, Cohen A, Hershako C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24.

11. Grady RW, Berdoukas V, Rachmilewitz EA. Iron chelation therapy:metabolic aspects of combining deferiprone and deferoxamine.11th International Conference on Oral Chelation in the Treatment of Thalassaemia Major and Other Diseases. Catania, Italy:2001;74-78.

12. Breuer W, Empers MJJ, Pootrakul P. Deferoxamine-chelatable iron, a component of serum nontransfusion bound iron, used for assessing chelation therapy. Blood 2001; 97:792-798.

13. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hyper transfused rats with labeled iron stores and in iron loaded rat heart cells in culture. J Lab Clin Med. 2001;138:130-138.

14. Porter JB. Deferoxamine pharmacokinetics. Semin Hematol. 2001;38:63–8.

15. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89(10):1187-1193.

16. Wonke B. Clinical management of beta-thalassemia major. Semin Hematol 2001; 38:350–9.

17. Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003; 10:1065–76.

18. Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, et al. ICL670A: preclinical profile. Adv Exp Med Biol 2002; 509:185-203.

19. Cohen AR .New Advances in Iron Chelation Therapy. Hematology 2006; 42-47.

20. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet, 2002.360:516-20.

21. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, et al. Combined therapy with deferiprone and desferrioxaminein thalassemia major. Haematologica 2005; 90:1309-14.

22. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, et al. Iron chelation treatment with combined therapy with deferiprone and deferoxamine: a 12-month trial. Blood Cells Mol Dis 2006;36:21-5.

23.Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood, 2003.102:1583-7.

24. Al_Refaie FN, Hershako C, Hoffbrand A, Kosaryan M, Olivieri NF, Tondury P, et al. Results of longterm deferiprone (L1) therapy: a report by the International Study Group on Oral iron Chelators.Brit J Haematol.1995;91:224-9.

25. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.Br J Haematol. 2002;118:330-6.

Keikhaei BMD .Major Thalassemia with Iron Overload: Sequential Deferoxamine-Deferasirox Treatment. World Journal Of Hematology And Oncology 2022.